Cargando…
A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Moderna COVID-19 Vaccine (mRNA-1273)
The Brighton Collaboration Benefit-Risk Assessment of VAccines by TechnolOgy (BRAVATO) Working Group has prepared standardized templates to describe the key considerations for the benefit-risk assessment of several vaccine platform technologies, including nucleic acid (RNA and DNA) vaccines. This pa...
Autores principales: | Leav, Brett, Straus, Walter, White, Phil, Leav, Alison, Gaines, Tashawnee, Maggiacomo, Grace, Kim, Denny, Smith, Emily R., Gurwith, Marc, Chen, Robert T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author(s). Published by Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9181264/ https://www.ncbi.nlm.nih.gov/pubmed/35753841 http://dx.doi.org/10.1016/j.vaccine.2022.06.005 |
Ejemplares similares
-
A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Medigen COVID-19 protein vaccine
por: Estephan, Lila, et al.
Publicado: (2023) -
The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of protein vaccines
por: Kochhar, Sonali, et al.
Publicado: (2020) -
The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of viral vector vaccines
por: Condit, Richard C, et al.
Publicado: (2020) -
A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for an inactivated viral vaccine against Chikungunya virus
por: Hernandez, Libia Milena, et al.
Publicado: (2022) -
The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of inactivated viral vaccines
por: Kochhar, Sonali, et al.
Publicado: (2020)